Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Fineline Cube Mar 19, 2026
Company Deals

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

Fineline Cube Mar 19, 2026
Company Deals

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

Fineline Cube Mar 19, 2026
Company Deals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Fineline Cube Mar 19, 2026
Company Deals

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Fineline Cube Mar 19, 2026
Policy / Regulatory

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Fineline Cube Mar 19, 2026
Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Fineline Cube Mar 19, 2026
Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Fineline Cube Mar 19, 2026
Company Drug

Frontier Biotechnologies Gains CDE Approval for FB2001 COVID-19 Inhalant Study

Fineline Cube Nov 24, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced receiving approval from the Center for Drug...

Company Drug

Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer

Fineline Cube Nov 24, 2022

China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the...

Company Drug

Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug

Fineline Cube Nov 24, 2022

China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II...

Company Drug

Kintor Pharma’s GT20029 Shows Positive Results in Phase I Study for Androgenetic Alopecia and Acne

Fineline Cube Nov 24, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive results from a Phase I clinical...

Company Drug Legal / IP

FibroGen Sues Former Employees and Two Pharma Firms for Trade Secret Theft

Fineline Cube Nov 23, 2022

US-based FibroGen Inc. has filed a lawsuit against two former employees, Liu Dong and Deng...

Company Deals

JS InnoPharm and Strategia Holdings Form JSI Ventures in Boston

Fineline Cube Nov 23, 2022

Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to...

Company Deals

Jianke.com Files for Hong Kong IPO with Focus on Chronic Disease Management

Fineline Cube Nov 23, 2022

China-based smart healthcare service platform Jianke.com (Fangzhou Inc.) has filed for an initial public offering...

Company Drug

China’s First Gene Therapy for Deafness, RRG-003, Begins Clinical Study

Fineline Cube Nov 23, 2022

RRG-003, an adeno-associated virus (AAV) gene therapy co-developed by China’s Shanghai Dingxin Gene Technology Co.,...

Policy / Regulatory

Shanghai Hosts Yangtze River Delta Alliance VBP Tender for 44 Drugs

Fineline Cube Nov 23, 2022

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a document indicating that the city will...

Company Drug

BeiGene to Present Final PFS Results for Brukinsa at ASH Meeting

Fineline Cube Nov 23, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced plans to present...

Company Deals

Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening

Fineline Cube Nov 23, 2022

Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a...

Company Deals Medical Device

Endoso Life Raises Pre-Series A Funding for High-End Medical Endoscope Development

Fineline Cube Nov 23, 2022

Endoso Life, a Hangzhou-based developer of high-end medical endoscope systems and devices, has reportedly raised...

Company Drug

Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation

Fineline Cube Nov 23, 2022

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA

Fineline Cube Nov 23, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the...

Company Drug

InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore

Fineline Cube Nov 23, 2022

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...

Company Deals

Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma

Fineline Cube Nov 23, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the...

Company Deals

UB Biotechnology Secures Series A Funding for Flow Cytometry Platform

Fineline Cube Nov 22, 2022

China-based in vitro diagnostics (IVD) maker UB Biotechnology (Zhejiang) Co., Ltd has reportedly raised “tens...

Company Deals

IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform

Fineline Cube Nov 22, 2022

China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...

Policy / Regulatory

Shanghai Unveils Policies to Boost Global Biomedical R&D Hub

Fineline Cube Nov 22, 2022

The Shanghai municipal government has released a set of policies and measures aimed at accelerating...

Company

WuXi Biologics Launches Integrated Biologics CRDMO Center in Shanghai

Fineline Cube Nov 22, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its...

Posts pagination

1 … 567 568 569 … 636

Recent updates

  • Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients
  • Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer
  • Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma
  • InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis
  • Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Company Drug

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

Company Drug

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.